Prostate cancer: open trials in Sweden

38 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

NCT06136624
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Sahlgrenska University Hospital-Vastra Gotalandsregionen, Goteborg · Karolinska University Hospital, Solna · Uppsala University Hospital, Uppsala
Registry updated 2026-11-05
NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Trial Treatment · Phase 3 · Pfizer
Soedersjukhuset AB, Stockholm
Registry updated 2026-10-30
NCT06925737
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Region Skane Skanes Universitetssjukhus, Malmo · Karolinska University Hospital, Solna · Soedersjukhuset AB, Stockholm · Uppsala University Hospital, Uppsala
Registry updated 2026-10-30
2022-502285-24-00
Study to assess the safety and efficacy of the SpectraCure P18 System
Trial Treatment · Phase 1/2 · SpectraCure AB (publ)
Region Skane Skanes Universitetssjukhus, Malmo
Registry updated 2026-10-27
NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Karolinska University Hospital, Solna · Uppsala University Hospital, Uppsala
Registry updated 2026-10-20
NCT07344779
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Research · Bayer
Many Locations, Many Locations
Registry updated 2026-10-19
NCT07611110
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Trial Treatment · Phase 3 · AstraZeneca
Stockholm · Umeå
Registry updated 2026-10-19
NCT06446401
The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Research · Uppsala University
Uppsala University, Uppsala · Uppsala University Hospital, Uppsala
Registry updated 2026-10-14
NCT06952803
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Trial Treatment · Phase 3 · AstraZeneca
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Region Skane Skanes Universitetssjukhus, Malmo · Karolinska University Hospital, Solna · Capio S:t Goerans Sjukhus AB, Stockholm · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2026-10-14
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Region Skane Skanes Universitetssjukhus, Lund · Karolinska Universitets Sjukhuset,Studie behandlingsavdelning, B08:09, Stockholm
Registry updated 2026-10-05
NCT06719206
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Trial Treatment · Mälardalen University
Akademiska sjukhuset, Uppsala · Västmanlands sjukhus, Västerås
Registry updated 2026-10-01
NCT05448547
Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
Trial Treatment · Phase 3 · Sven Löffeler
Falu Lasarett, Falun · Sahlgrenska University Hospital, Gothenburg · Helsingborg/Ängelholm hospital, Helsingborg · Örebro University Hospital, Örebro · Östersunds Hospital, Östersund · Södersjukhuset, Stockholm · Capio Saint Göran's Hospital, Stockholm · Norrlands universitetssjukhus, Umeå · Akademiska sjukhuset, Uppsala, Uppsala
Registry updated 2026-09-10
2026-527110-23-00
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
Trial Treatment · Phase 2 · Region Uppsala
Region Uppsala, Uppsala
Registry updated 2026-08-12
NCT06217822
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Trial Treatment · Phase 1 · Bayer
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna · Uppsala University Hospital, Uppsala
Registry updated 2026-07-07
2025-520571-66-00
CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids.
Trial Treatment · Phase 3 · Region Vaesterbotten
Region Vaesterbotten, Umea
Registry updated 2026-06-11
NCT05803941
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Sahlgrenska University Hospital-Vastra Gotalandsregionen, Goteborg · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna
Registry updated 2026-06-04
NCT06474806
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
Trial Treatment · Phase 2 · Curasight
Gothenburg University Vaccine Research Institute, Gothenburg · Lunds Universitet, Lund
Registry updated 2026-06-01
NCT07617272
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
Trial Treatment · Phase 2 · Region Stockholm
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Solna
Registry updated 2026-06-01
NCT03151629
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Research · Prostate Cancer Clinical Trials Consortium
Skåne University Hospital, Malmö · Örebro University Hospital, Örebro · Umeå University Hospital, Umeå
Registry updated 2026-05-22
NCT03067051
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Trial Treatment · Phase 1/2 · SpectraCure AB
Skåne University Hospital, Malmö
Registry updated 2026-05-01
NCT04916613
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Trial Treatment · Phase 3 · UNICANCER
Sahlgrenska University Hospital-Vastra Gotalandsregionen, Gothenburg · Universitetssjukhus, Malmö
Registry updated 2026-04-28
NCT06363435
AI-based Measurements of Tumour Burden in PSMA PET-CT
Research · Elin Tragardh
Skåne University Hospital, Lund · Skåne University Hospital, Malmö
Registry updated 2026-04-28
NCT04983095
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
Trial Treatment · Karin Soderkvist
Ryhovs county hospital, Jönköping · Region Skane, Lund · Region Orebro lan, Orebro · Södersjukhuset, Stockholm · Capio St Göran Hospital, Stockholm · Karolinska University Hospital, Stockholm · Umeå University Hospital, Umeå
Registry updated 2026-02-17
NCT05264337
Lymphedema After Urologic Surgery
Research · Vastra Gotaland Region
Sahlgrenska University Hospital, Gothenburg · Örebro University Hospital, Örebro
Registry updated 2026-01-16
NCT04858880
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
Trial Treatment · Lund University Hospital
Jönköping County Hospital, Ryhov, Jönköping · Kalmar County Hospital, Kalmar · Lund University Hospital, Lund
Registry updated 2025-09-16

All Prostate cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error